Tags : Collaborates

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar)

Vartika Singh October 25, 2018

Shots: Amgevita is indicated to treat chronic inflammatory diseases such as moderate-to-severe RA, IBD and psoriasis Amgen Biosimilar Amgevita, is a novel adalimumab’s biosimilar to be marketed in Finland. On […]readmore

M&A

Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat

Vartika Singh October 11, 2018

Shots: Ionis to get $75M upfront plus $684M as development, regulatory, sales milestones, license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for […]readmore

M&A

Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor

Vartika Singh September 26, 2018

Shots: Collaboration is for development of novel drugs utilizing B. longum as a drug delivery carrier for in-situ Delivery and Production System (i-DPS) Technology. Astellas has option rights to further […]readmore

Tags : Collaborates

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar)

Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat

Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Collaborates

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar)

Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat

Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company